Evidence map›Paper›PMID 32358094›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020

Impact of

Wolfgang P Fendler, Justin Ferdinandus, Johannes Czernin, Matthias Eiber, Robert R Flavell, Spencer C Behr, I-Wei K Wu, Courtney Lawhn-Heath, Miguel H Pampaloni, Robert E Reiter and 8 more

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 5 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 5 syntheses or guidelines pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Trial
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Patterns of failure withCanadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025
    Article
  17. Article
  18. Head-to-head comparison ofFrontiers in oncology · 2025
    Article
  19. Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Wolfgang P FendlerAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Justin FerdinandusDepartment of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Germany.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Matthias EiberAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Robert R FlavellDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Spencer C BehrDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
I-Wei K WuDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Courtney Lawhn-HeathDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Miguel H PampaloniDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Robert E ReiterDepartment of Urology, UCLA Medical Center, UCLA, Los Angeles, California.
Matthew B RettigDepartment of Urology, UCLA Medical Center, UCLA, Los Angeles, California.
Jeannine GartmannAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Vishnu MurthyDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Roger SlavikAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Peter R CarrollDepartment of Urology, University of California, San Francisco, San Francisco, California.
Ken HerrmannAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Thomas A HopeDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California thomas.hope@ucsf.edu.
University of California, San Francisco · USDeutschen Konsortium für Translationale Krebsforschung · DEKlinikum rechts der Isar · DEUCLA Medical Center · USVA Greater Los Angeles Healthcare System · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
MELT: Modulation of PSMA Expression for Lutetium TherapyR01CA235741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS A · 2019 to 2025
$3.2M
Qualification and Harmonization of PET/MRI for Cancer Clinical TrialsR01CA212148 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS, LAFOREST, RICHARD ANDRE · 2017 to 2022
$2.7M
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA212148
6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA) ligand PET induces management changes in patients with prostate cancer. We aim to better characterize the impact of

Indexed as

OligopeptidesAdultAgedAged, 80 and overEdetic AcidGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedProspective StudiesProstatic NeoplasmsRecurrenceEdetic Acidgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesOligopeptidesBCRchange in managementimpactmolecular imagingPETprostate cancer

Identifiers

PMID32358094
PMCPMC9364898
OpenAlexW3022545744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.